- Home
- CGTL vs ACHV Comparison
CGTL vs ACHV Comparison
Compare CGTL & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTL
- ACHV
- Stock Information
- Founded
- CGTL 2016
- ACHV N/A
- Country
- CGTL Hong Kong
- ACHV Canada
- Employees
- CGTL N/A
- ACHV N/A
- Industry
- CGTL
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CGTL
- ACHV Health Care
- Exchange
- CGTL NYSE
- ACHV Nasdaq
- Market Cap
- CGTL 152.2M
- ACHV 149.6M
- IPO Year
- CGTL 2024
- ACHV N/A
- Fundamental
- Price
- CGTL $9.28
- ACHV $4.16
- Analyst Decision
- CGTL
- ACHV Strong Buy
- Analyst Count
- CGTL 0
- ACHV 5
- Target Price
- CGTL N/A
- ACHV $14.80
- AVG Volume (30 Days)
- CGTL 320.8K
- ACHV 113.3K
- Earning Date
- CGTL 01-01-0001
- ACHV 11-07-2024
- Dividend Yield
- CGTL N/A
- ACHV N/A
- EPS Growth
- CGTL N/A
- ACHV N/A
- EPS
- CGTL 0.14
- ACHV N/A
- Revenue
- CGTL $42,953,944.00
- ACHV N/A
- Revenue This Year
- CGTL N/A
- ACHV N/A
- Revenue Next Year
- CGTL N/A
- ACHV N/A
- P/E Ratio
- CGTL $66.26
- ACHV N/A
- Revenue Growth
- CGTL N/A
- ACHV N/A
- 52 Week Low
- CGTL $3.37
- ACHV $3.20
- 52 Week High
- CGTL $10.59
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- CGTL N/A
- ACHV 38.34
- Support Level
- CGTL N/A
- ACHV $4.07
- Resistance Level
- CGTL N/A
- ACHV $4.66
- Average True Range (ATR)
- CGTL 0.00
- ACHV 0.18
- MACD
- CGTL 0.00
- ACHV -0.03
- Stochastic Oscillator
- CGTL 0.00
- ACHV 22.23
About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED
Creative Global Technology Holdings Ltd Conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.